Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.46 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.44 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.44 |
| ▸ | RPS17 | P08708 | 1/20 | 0.44 |
| ▸ | RPSA | P08865 | 1/20 | 0.44 |
| ▸ | RPS2 | P15880 | 1/20 | 0.44 |
| ▸ | RPL35A | P18077 | 1/20 | 0.44 |
| ▸ | RPL7 | P18124 | 1/20 | 0.44 |
| ▸ | RPL17 | P18621 | 1/20 | 0.44 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.44 |
| ▸ | RPS3 | P23396 | 1/20 | 0.44 |
| ▸ | RPS12 | P25398 | 1/20 | 0.44 |
| ▸ | RPL13 | P26373 | 1/20 | 0.44 |
| ▸ | RPL10 | P27635 | 1/20 | 0.44 |
| ▸ | RPL12 | P30050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341939 | 0.94 | ALOX5 (0.60) | ALOX5OPRM1SIGMAR1C5AR1MBTPS1 | |
| SCHEMBL4207728 | 0.86 | OPRM1 (0.57) | ALOX5OPRM1SIGMAR1C5AR1CCR5 | |
| SCHEMBL4912849 | 0.85 | ALOX5 (0.52) | ALOX5OPRM1C5AR1MBTPS1KCNH2 | |
| SCHEMBL4210498 | 0.83 | MBTPS1 (0.59) | ALOX5MBTPS1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL18143029 | 0.81 | OPRM1 (0.49) | ALOX5OPRM1MBTPS1KCNH2SLC6A2 | |
| SCHEMBL11448021 | 0.81 | CHRM3 (0.52) | ALOX5OPRM1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL9678944 | 0.81 | SLC6A4 (0.47) | OPRM1KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4205921 | 0.81 | OPRM1 (0.49) | ALOX5OPRM1SIGMAR1C5AR1ALDH1A1 | |
| SCHEMBL5036802 | 0.80 | DCUN1D1 (0.47) | ALOX5OPRM1KCNH2SLC6A2SLC6A4 | |
| SCHEMBL4922736 | 0.80 | PKM (0.65) | ALOX5OPRM1SIGMAR1C5AR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-4664564-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| JP-2003531829-A | — | — | 2003-10-28 | — | — | JP | claimed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | claimed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALOX5 614/4885OPRM1 210/4885SIGMAR1 295/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALOX5 614/4885OPRM1 210/4885SIGMAR1 295/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | ALOX5 614/4885OPRM1 210/4885SIGMAR1 295/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | ALOX5 275/4885OPRM1 73/4885SIGMAR1 208/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | ALOX5 631/4885OPRM1 193/4885SIGMAR1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.